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Sir
It was with great interest that we read the letter to the Editor from
Vermeulen et al (1999) regarding the accuracy of the measurement
of vascular endothelial growth factor (VEGF) serum levels
(VEGF-SL) and VEGF plasma levels (VEGF-PL) in cancer
patients (Vermeulen et al, 1999). We have measured about 1000
serum samples for VEGF and should thus like to comment on their
observations based on our findings:
1. We agree with Vermeulen et al that interindividual and intra-
individual fluctuations of serum VEGF levels can, at least in
part, be explained by variations of blood platelet counts.
Another factor that may contribute to the variability of serum
VEGF levels is the platelet volume. This notion is substanti-
ated by our findings from patients receiving myeloablative
chemotherapy. In these patients, screening of VEGF-SL was
begun prior to the platelet nadir (< 20 G l—1) and continued
until the platelet counts had been recovered. VEGF was
measured in 140 serum samples and 54 corresponding plasma
samples by enzyme-linked immunosorbent assay (ELISA),
essentially as described by Vermeulen et al. In line with their
results, we found a striking correlation between peripheral
blood platelet counts and absolute values of VEGF-SL (r =
0.8; P < 0.001), but not with VEGF-PL. Like Vermeulen and
colleagues, we noted a broad inter-individual and intra-indi-
vidual variability of VEGF-SL values. Thus, we hypothesized
that VEGF-SL may not only depend on blood plaletet counts
but also on the plaletet size. Platelets freshly released from the
bone marrow following myeloablative chemotherapy may
differ in size from those produced during a steady-state of
myelopoiesis. To test this hypothesis, we compared the mean
platelet volumes (MPV) prior to the platelet nadir with the
MPV during the time of platelet reconstitution by using an
electronic particle counter. In peripheral blood, the MPV
before the platelet nadir indeed proved to be significantly
lower than afterwards. Even if VEGF-SL values were
corrected for the actual blood platelet count (VEGFPLT =
VEGF-SL ´ 106 platelets/actual blood platelet count),
VEGFPLT values prior to the platelet nadir were significantly
lower than those measured afterwards (Figure 1).
2. In vivo, platelet activation or platelet destruction causes major
increments in VEGF blood levels: we detected high VEGF
levels in both serum and plasma samples indicating a massive
release of VEGF during intravasal platelet destruction in a
patient with thrombotic-thrombocytopenic purpura.
3. Tumour cells and/or blood platelets may be the major sources
of VEGF in cancer patients, particularly in metastatic disease.
In fact, the majority of cancer patients with metastatic disease
show elevated VEGF levels in serum (Kraft et al, 1999).
Moreover, increasing VEGF serum levels may herald tumour
relapse or progression. In a patient with breast cancer under-
going adjuvant high-dose chemotherapy, we noted a rapid
the rationale for the potential efficacy of finasteride in preventing
prostate cancer. We began our study fully expecting to observe
beneficial effects on prostate cancer. Unfortunately we did not.
Although, we, too, were somewhat surprised by the low inci-
dence of prostate cancer in the observational arm at the 1-year
follow-up biopsy, we doubt that Coltman would have found
acceptable a trial utilizing possibly inappropriate historical
controls. The notion that you can change an observation in a trial
and modify statistical values is hardly novel, and belies the entire
purpose of statistical testing. Coltman raises the issue that if the
cancer detection rate had been 7/27 and 1/25 in the treated and
untreated groups, the P-value of the difference would be 0.051.
Although this does not reach ￿statistical significance￿, we would
have considered such a difference to be very worrisome.
Coltman then states that if the patients with PIN are removed,
the difference in cancer detection rates is meaningless. Two points
can be made: (1) a clear and important conclusion of our study is
that the presence of PIN is a strong risk factor for developing a
positive biopsy after finasteride treatment; (2) in men without PIN
the effect of finasteride on the diagnosis of prostate cancer is
￿meaningless￿ because of small numbers. However, the much
larger study referred to by Coltman of McConnel et al (1998) did
not find a protective effect of finasteride either. In the latter trial, a
total of 3040 men were randomized to receive finasteride or
placebo for the treament of symptoms of benign prostatic hyper-
plasia. Treatment was for 4 years; in order to monitor for prostate
cancer, 645 men underwent prostate biopsies during the study (325
men in the finasteride group and 320 men in the placebo group).
The incidence of prostate cancer was 5% in each group, indicating
no reduction in prostate cancer risk in a large population of lower
risk men undergoing long-term treatment with finasteride.
Coltman repeatedly points to the small size of our trail.
However, we were faced with the serious dilemma in the interim
analysis of our study, that we might be causing harm. We decided
that we could not justify continuing to accrue additional subjects.
Our trial, while small, remarkably provides the only data of any
kind to date on the biological effects of finasteride on human
prostate tissue. We strongly feel that studies such as ours are essen-
tial before embarking on large scale, long-term multi-institutional
trials in healthy individuals. We undertook our study because of
the dearth of any such relevant information.
As Chairman of the Southwest Oncology Group under whose
auspices the US National Prostate Cancer Prevention Trial is being
conducted, we believe the results of our study merit Dr Coltman￿s
attention, and should not be dismissed on dubious statistical grounds.
RK Ross, MC Pike, E Skinner and RJ Cote
University of Southern California, School of Medicine,
1441 Eartlake Avenue, Los Angeles, CA 90033-0800, USA
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increase in the VEGFPLT value from 2.1 ± 1.0 pg during the
time of remission to 6.75 pg at the time of clinical relapse.
This increment in VEGFPLT could be due to a release of VEGF
from a fast-growing tumour mass and/or from tumour-
activated platelets (Pinedo et al, 1998). We did indeed find
tumour cells to induce platelet activation and release of VEGF
from activated platelets (manuscript in preparation).
In summary, we agree with Vermeulen and colleagues that
VEGF levels in serum may be a useful tumour marker that relates
to the disease stage, tumour progression and tumour-induced
platelet activation. To correctly interpret serum VEGF levels,
however, blood platelet counts and the platelet size must be taken
into consideration.
E Gunsilius and G Gastl
Division of Hematology and Oncology, University Hospital,
Anichstr. 35, 6020 Innsbruck, Austria
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Figure 1 Mean platelet volumes (MPV, black columns) and corresponding
VEGFPLT (hatched columns) in a patient undergoing myeloablative
chemotherapy. MPV before the platelet nadir (A) were lower than those
thereafter (B, P = 0.001). Also, the VEGFPLT are lower before the platelet
nadir (C) than thereafter (D). VEGFPLT correlated to the MPV (r = 0.59)
Effect of acetic acid on telomerase activity in
premalignant and malignant cervical lesions
Sir
We read with great interest the report by Mutirangura et al (1998)
on defining a correlation between telomerase activity and human
papillomavirus (HPV) in normal control tissue and in benign,
premalignant and malignant cervical lesions.
We are convinced of the conclusion that there may be two roles
of telomerase in the cervix (the first one would present in benign
lesions; the second is associated with cancer development and acti-
vated during the late stage of multistep carcinogenesis). However,
we have doubt about the low percentages of telomerase activity
reported for high-grade squamous intraepithelial lesions (SILs) as
40%, and probably for others, especially after reading the article by
Changchien et al (1998). The studies of many authors revealed that
25—58% of high-grade SILs exhibited telomerase activity (Kyo et
al, 1997; Pao et al, 1997; Zheng et al, 1997). However, Changchien
et al reported a relative high percentage of telomerase activity
(77.1%) in high-grade SILs. The large discrepancy between the
results of previous studies and the results of them were explained
by the methods of cervical tissue collection. They claimed that they
increased the detection rate of telomerase activity by making the
tissues submitted for telomerase assay free of acetic acid.
It is well known that swabbing of cervix with 3—5% acetic acid
is a crucial step when colposcopy is performed. Since some of the
samples of Mutirangura et al were also obtained by this way, those
samples could have been affected by acetic acid. Due to the reason
that pH of 5% acetic acid is too low and exposure time is too long,
telomerase protein is probably irreversibly denatured by this
process (Lodish et al, 1995).
We would like to stress that if ￿acetic acid￿ factor is taken into
consideration in such studies, much higher telomerase detection
rates and eventually much more accurate results of it are possible
to be obtained.
IH Güllü and M Kurdog ˘lu
Institute of Oncology, Hacettepe University, Sihhiye 06100,
Ankara, Turkey.
REFERENCES
Chang Chien C, Lin H, Leung SW, Hsu C and Cho C (1998) Effect of acetic acid on
telomerase activity in cervical intraepithelial neoplasia. Gynecol Oncol 71:
99—103
Kyo S, Takakura M, Ishikawa H, Sasagawa T, Satake S, Tateno M and Inouc M
(1997) Application of telomerase assay for the screening of cervical lesions.
Cancer Res 57: 1863—1867
Lodish H, Baltimore D, Berk A, Zipursky Lawrence S, Matsudira P and Darnell J
(1995) A protein can be unfolded by heat, extreme pH and certain chemicals in
molecular cellular biology. In: Protein Structure and Function, 3rd edn,
pp. 73—75. Scientific American Books
Mutirangura A, Sriuranpong V, Termrunggraunglert W, Tresukosol D,
Lertsaguansinchai P, Voravud N and Niruthisard S (1998) Telomerase activity
and human papillomavirus in malignant, premalignant and benign cervical
lesions. Br J Cancer 78: 933—939
Pao CC, Tseng CJ, Lin CY, Yang FP, Hor JJ, Yao DS and Hsueh S (1997)
Differential expression of telomerase activity in human cervical cancer and
cervical intraepithelial neoplasia lesions. J Clin Oncol 15: 1932—1937
Zheng PS, Iwasawa T, Yokoyama M, Nakao Y, Pater A and Sugimori H (1997)
Telomerase activation in in vitro and in vivo cervical carcinogenesis. Gynecol
Oncol 66: 222—226